Luis Ontiveros-Padilla

Mr. Luis Ontiveros-Padilla

Mexican Social Security Institute
+1
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
SYSelin Yüksel
Selin Yüksel
MPMert Pekcan
Mert Pekcan
NPNuhan Puralı
Nuhan Puralı
GEGüneş Esendağlı
Güneş Esendağlı
ETEce Tavukcuoglu
Ece Tavukcuoglu
SŞSevda Şenel
Sevda Şenel

22 January 2024 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
EPErik S. Pena
Erik S. Pena
CBCole J. Batty
Cole J. Batty
DHDylan A. Hendy
Dylan A. Hendy
SYShuangshuang Yang
Shuangshuang Yang
Luis Ontiveros-PadillaLuis Ontiveros-Padilla
Luis Ontiveros-Padilla
EBEric M. Bachelder
Eric M. Bachelder

20 December 2023 in Advanced Therapeutics
Verified
Journal Article
Closed access
DHDylan A. Hendy
Dylan A. Hendy
EPErik S. Pena
Erik S. Pena
CBCole J. Batty
Cole J. Batty
Luis Ontiveros-PadillaLuis Ontiveros-Padilla
Luis Ontiveros-Padilla
JIJohn A. Roque Iii
John A. Roque Iii
KAKristy M Ainslie
Kristy M Ainslie

1 April 2024 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
JRJohn A. Roque
John A. Roque
NLNicole Rose Lukesh
Nicole Rose Lukesh
DHDylan A. Hendy
Dylan A. Hendy
TDTimothy A. Dixon
Timothy A. Dixon
JIJahirul Islam
Jahirul Islam
KAKristy M Ainslie
Kristy M Ainslie

7 April 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
Luis Ontiveros-PadillaLuis Ontiveros-Padilla
Luis Ontiveros-Padilla
AGAlberto García-Lozano
Alberto García-Lozano
ATAraceli Tepale
Araceli Tepale
TRTania Rivera-Hernandez
Tania Rivera-Hernandez
RPRodolfo Pastelin-Palacios
Rodolfo Pastelin-Palacios
CLConstantino López-Macías
Constantino López-Macías
Salmonella enterica serovar Typhi (S. Typhi) porins, OmpC and OmpF, are potent inducers of the immune response against S. Typhi in mice and humans. Vaccination with porins induces the protection against 500 LD50 of S. Typhi, life-lasting bactericidal antibodies and effector T cell responses in mice; however, the nature of the memory T cell compartment and its contribution to protection remains unknown. In this work, we firstly observed that vaccination with porins induces in situ (skin) CD4+ and CD8+ T cell responses. Analysis of the porin-specific functional responses of skin CD4+ and CD8+ T cells showed IFN-gamma- and IL-17-producing cells in both T cell populations. The memory phenotype of porin-specific T cells indicated the presence of resident and effector memory phenotypes in the skin, and a central memory phenotype in the skin-draining lymph node. In addition, we demonstrated that vaccination with porins via skin reduces the bacterial burden following challenge. Finally, evaluating the role of the circulating T cell memory population in protection, we showed that circulating memory CD4+ and CD8+ T cells are crucial in porin-mediated protection against S. Typhi. Overall, this study highlights the importance of inducing circulating memory T cell responses in order to achieve the optimal protection provided by porins, showing a mechanism that could be sought in the rational development of vaccines.

4 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
ATAlejandro Torres-Flores
Alejandro Torres-Flores
Luis Ontiveros-PadillaLuis Ontiveros-Padilla
Luis Ontiveros-Padilla
Ruth Madera-SandovalRuth Madera-Sandoval
Ruth Madera-Sandoval
ATAraceli Tepale
Araceli Tepale
JMJulian Argenis Gajon Martinez
Julian Argenis Gajon Martinez
CLConstantino López-Macías
Constantino López-Macías
Several effective vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and implemented in the population. However, the current production capacity falls short of meeting global demand. Therefore, it is crucial to further develop novel vaccine platforms that can bridge the distribution gap. AVX/COVID-12 is a vector-based vaccine that utilizes the Newcastle Disease virus (NDV) to present the SARS-CoV-2 spike protein to the immune system. This study analyses the antigenicity of the vaccine candidate by examining antibody binding and T-cell activation in individuals infected with SARS-CoV-2 or variants of concern (VOCs), as well as in healthy volunteers who received coronavirus disease 2019 (COVID-19) vaccinations. Our findings indicate that the vaccine effectively binds antibodies and activates T-cells in individuals who received 2 or 3 doses of BNT162b2 or AZ/ChAdOx-1-S vaccines. Furthermore, the stimulation of T-cells from patients and vaccine recipients with AVX/COVID-12 resulted in their proliferation and secretion of interferon-gamma (IFN-γ) in both CD4+ and CD8+ T-cells. In conclusion, the AVX/COVID-12 vectored vaccine candidate demonstrates the ability to stimulate robust cellular responses and is recognized by antibodies primed by the spike protein present in SARS-CoV-2 viruses that infected patients, as well as in the mRNA BNT162b2 and AZ/ChAdOx-1-S vaccines. These results support the inclusion of the AVX/COVID-12 vaccine as a booster in vaccination programs aimed at addressing COVID-19 caused by SARS-CoV-2 and its VOCs.